Abstract: Modelling a molecule by means of a graph, said graph comprising vertices and edges, each edge having a specific type, and said graph having cyclic orderings on the half-edges about at least one of the vertices, said system comprising means for determining the cyclic orderings on the half-edges about said at least one vertex by means of the spatial coordinates of the constituent atoms of the molecule, and means for determining the type of each edge of the graph by means of the relative spatial location of the constituent atoms of the molecule. Thereby automatic classification, comparison, specification, analysis and/or prediction of molecular structures can be provided because these molecular structures are represented by explicit combinatorial objects, and descriptors can be derived from the graph constructed in this manner. The descriptors are automatically computable from molecular databases, such as PDB or CATH, with no qualitative human intervention or subjective criteria.

Abstract: A thermoelectric material of the p-type having the stoichiometric formula Zn4Sb3, wherein part of the Zn atoms optionally being substituted by one or more elements selected from the group comprising Sn, Mg, Pb and the transition metals in a total amount of 20 mol % or less in relation to the Zn atoms is provided by a process involving zone-melting of a an arrangement comprising an interphase between a “stoichiometric” material having the desired composition and a “non-stoichiometric” material having a composition deviating from the desired composition. The thermoelectric materials obtained exhibit excellent figure of merits.

Abstract: A biocompatible material, wherein at least a part of a surface of the biocompatible material is characterized by a micro or nano-meter scale topographical structure comprising a plurality of features where the structure is selected to promote the growth of undifferentiated pluripotent stem cells or serve to promote the uniform differentiated growth of stem cells. Furthermore, a biocompatible material is provided having a surface structure and composition that affects a cellular function, in particular cellular functions related to gene induction, cell differentiation and the formation of bone tissue in vivo and ex-vivo.

Abstract: The present invention relates to dehydrated nanoparticles comprising chitosan and a nucleic acid. Preferably, the nucleic acid is a siRNA. Dehydrated nanoparticles of the invention have improved storage characteristics. The particles may be used in screening methods, e.g. where they have been dried onto a solid support, such as the surface of a culture well. The nanoparticles may also be dried onto implants for tissue engineering scaffolds, where they enable transfection of cells growing on the scaffold. Moreover, the particles have therapeutic relevance.

Abstract: There is disclosed a driving and steering wheel (112) module (102) with an omni rotational part (106), the module comprising a flange part (104) fixable on a robot, and the omni rotational part (106) comprises an upper omni rotational part (105) and a driving and steering wheel part (108), where the omni rotational part (106) is provided for infinite rotation relative to the flange part (104) by both a drive motor (110) and a steering motor (114) being positionable on the flange part (104), and the driving and steering wheel part (108) is suspended from the upper omni rotational part (105) with a suspension (116) such that wheel part (108) can move relatively to the upper omni rotational part (105) in a suspension direction (118), and a reduction gear (120) for gearing the drive torque is provided in the wheel part (108) in order e.g. to assure traction on various surfaces and at various loads.

Abstract: The invention relates to the use of benzoxazinoids-containing grains of cereals for the production of food and beverage products with health-improving effects. Especially the invention relates to the use of benzoxazinoids-containing grains of cereals for the production of bread baked on rye grains, wheat, spelt, rye and/or spelt sprouts for health-improving purposes. The health-improving effects according to the invention are obtained through the CNS stimulating effects of said benzoxazinoid-containing food and beverage products. These effects are appetite suppression, enhancement of mood, improved sexual function, relieve of fibromyalgia and sleep apnea disorders. Other CNS-related disorders are included as well. The health-improving effects of the invented food products containing benzoxazinoids also include anti-cancer activity, anti-inflammatory effects, analgesic effects and antibacterial effects.

Abstract: The present invention relates to a crystal structure of a plasma membrane proton pump type ATPase. The invention further describes method for identification of modulators of ATPases as well as uses of such modulators. Based on the provided three dimensional structure of the ATPase, various method, such as computer implemented methods may be used for identification of modulators, such putative modulators may be further analysed using in vitro and in vivo experiments to confirm there functionality. Several modulator interaction regions are described as target of regulation by ATPase modulators.

Abstract: The present invention provides nanoparticles for treatment of inflammatory diseases. The nanoparticles preferably comprise chitosan and a siRNA targeting a mRNA encoding a pro-inflammatory cytokine, such as e.g. tnf-alfa. A preferred route of administration of the nanoparticles is by injection intraperitoneally.

Abstract: The present invention relates to nanoparticles comprising osteopontin and a polymer carrier, preferably a cationic carrier. Preferably, the cationic carrier is chitosan. Osteopontin and/or the cationic carrier may have bioactivity and/or the nanoparticle may comprise an additional component with bioactivity. Such additional bioactive component may e.g. be a siRNA. The nanoparticles of the invention may be used for treatment of bone diseases or inflammatory diseases.

Abstract: There is disclosed a wireless silage 104 sensor unit 102 with one or more sensors 402, 404, 406, 408 for sensing physical and/or chemical characteristics of the silage, and a transmitter 410 coupled to the one or more sensors for wirelessly transmitting the characteristics. A size and/or a shape of the sensor unit 102 is adapted for sensor unit 102 to be embedded in the silage 104 during storage of the silage and for the silage 104 to be provided with the sensor unit 102 during storage of the silage and for the sensor unit to endure a decompacting process of the silage during which the silage is decompacted and possibly mixed with further ingredients and where the sensor unit 102 is furthermore adapted to be sorted out unbroken after the decompacting process.

Abstract: The present invention concerns the detection of resistance in a living organism, e.g., herbicide resistance in weed crops. Based on non-separated compounds obtained from an organism, e.g., an extract from a plant, a color development is generated. The color or shade developed is dependent on the compounds of the organism. By comparing the color or shade of the extract obtained from an organism with a standard color scale developed with respect to the same organism, it is possible to determine if the organism is resistant to a pesticide, e.g., a herbicide. The invention also concerns a method of providing a standard color scale for material from a living organism that has been exposed to stress, e.g., a pesticide. As assay kit for the determination of whether material from a living organism is resistant to a pesticide is also described. The present invention may be used by farmers or advisors to test if the plants have developed resistance to a herbicide.

Abstract: The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, foetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

Abstract: The invention relates to the use of a thermoelectric material for thermoelectric purposes at a temperature of 150 K or less, said thermoelectric material is a material corresponding to the stoichiometric formula FeSb2, wherein all or part of the Fe atoms optionally being substituted by one or more elements selected from the group comprising: Sc, Ti, V, Cr, Mn, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Tr, Pt, Au, Hg, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu and a vacancy; and wherein all or part of the Sb atoms optionally being substituted by one or more elements selected from the group comprising: P, As, Bi, S, Se, Te, B, Al, Ga, In, Tl, C, Si, Ge, Sn, Pb and a vacancy; with the proviso that neither one of the elements Fe and Sb in the formula FeSb2 is fully substituted with a vacancy, characterised in that said thermoelectric material exhibits a power factor (S2?) of 25 ?W/cmK2 or more at a temperature of 150 K or less.

Abstract: The present invention relates to a modified pig as a model for studying Alzheimer's disease. The modified pig model displays one or more phenotypes associated with Alzheimer's disease. Disclosed is also a modified pig comprising a modified human and/or porcine APP gene, and/or PS1 gene, and/or a transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of Alzheimer's disease; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from Alzheimer's disease are disclosed.

Abstract: The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof and/or LDL gene or part thereof, and/or LDL receptor gene, and/or transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of atherosclerosis; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from atherosclerosis are disclosed.

Abstract: The present invention relates to a genetically modified pig as a model for studying psoriasis. The modified pig model displays one or more phenotypes associated with psoriasis. Disclosed is also a modified pig comprising a mutation in the endogenous ILK-I Ra, JunB/cJun, CD18, IKK2, and/or LIG1 gene, and/or a human, porcine and/or murine PPARs, PPAR-?, l?B-?, STAT3c, Integrin beta 1, Integrin alpha 2, MEK1, Amphiregulin, BMP-6, VEGF, JunB?ec-Jun?ep, IL-I a, TGF.beta 1, CD18 hypo, Cre/lkk2FL/FL, Dsg1, SCCE, TGF-a, TNF-a, IL-20, IFN-g, LIG1 KO, KGF, IL-6, PAFR1 Cre/lkk2FL/FL, IL1 R, Dsg3, IFN-gamma, p40, ILI Ra, IKK2, JunB/c-Jun, and/or LIG1 gene, transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of psoriasis, for screening the efficacy of a pharmaceutical composition, and a method for treatment of human being suffering from psoriasis are disclosed.

Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA 2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.

Abstract: The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.

Abstract: A system (202) is disclosed with a frame (204) with a plurality pivotable connected frame sections (214, 216, 220, 502), the frame (204) being operable in a number of positions (206, 302) and changeable between these, and a length adjustable connection (232) between at least one of the frame sections and a dragging device (212), wherein the length adjustable connection (232) is arranged in an angle (234) and a length (244) of the length adjustable connection is controlled so as to obtain drag forces created by working the soil, and the length adjustable connection (232) is so arranged that changing the length (244) of the length adjustable connection at least partly supports and at least partly powers a change of the position (206, 302) of the frame in order e.g. to provide an improved relation between a transport width and a soil working width of the frame (204) and for supporting, controlling and changing between multiple positions (206, 302).

Abstract: The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome.